Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - MA22
MA22 Details
Status: Closed 
Activation Date: 2003FEB25
Closing Date: 2009JUN08
Phase: I-II 

Description: A Phase I/II Study of Increasing Doses of Epirubicin and Docetaxel Plus Pegfilgrastim for Locally Advanced Or Inflammatory Breast Cancer 

Eligibility: To determine MTD and recommended phase II dose of docetaxel and epirubicin with pegfilgrastim in a phase I dose escalation study as 1st line therapy. To evaluate toxicity of the combination at the recommended phase II dose. To evaluate response rate and duration of the combination as first-line therapy at the recommended phase II dose. 

Objective: Women with locally advanced or inflammatory breast cancer; no previous surgical systemic or radiation treatment for breast cancer other than biopsy for diagnosis; ECOG 0, 1, 2; adequate blood counts; LVEF > institutional lower normal limit; no history of cardiac disease. 

Participation: Limited 

Lay Description: The purpose of this study is to find out what effect these drugs (epirubicin and docetaxel) have on and to find a more effective treatment for this type of breast cancer. It is thought that the two drugs, epirubicin and docetaxel when given together may be effective in shrinking tumours. This study will evaluate the safety and effectiveness of docetaxel and epirubicin when they are given together.  

Primary Publication Show

Other Publications Show

Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
BREAST MA22 93 41 40 41
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
BREAST MA22 93 3 40
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
BREAST MA22 93 0 0 0 0 0 0 0 0